Aurobindo arm’s copy of Novartis drug gets U.S. FDA nod

Aurobindo Pharma subsidiary Eugia Pharma Specialities has received last support from the U.S. Food and Drug Administration (U.S. FDA) to manufacture and marketplace Everolimus Tablets successful antithetic strengths.

The merchandise is bioequivalent and therapeutically equivalent to notation listed cause Zortress Tablets of Novartis Pharmaceuticals Corp. The support is for Eugia Unit-I and the merchandise is expected to beryllium launched successful archetypal 4th of FY27, Aurobindo Pharma said connected Thursday.

The approved merchandise has an estimated marketplace size of $78 cardinal for the 12 months ending December 2025, it said citing IQVIA MAT numbers.

Everolimus Tablets are indicated for the prophylaxis of organ rejection successful big patients receiving kidney oregon liver transplants. Aurobindo Pharma said this is the 184th ANDA approval, including 10 tentative approvals received, retired of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing some oncology oral and sterile specialty products.